Interleukin-17 Receptor A Antagonist

Interleukin 17 Receptor A Antagonists

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="ID_c1830e0a-cba5-46b5-9c99-6826fa188ac9"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.</p><p>SILIQ (brodalumab) Injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution delivered via subcutaneous injection. A few translucent to white, amorphous particles may be present. SILIQ is supplied in a single-dose 2.25 mL syringe made from type 1 glass with stainless steel 27G x ½” needle. Each SILIQ single-dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8.</p></section>

Siliq

brodalumab

1.5 ML brodalumab 140 MG/ML Prefilled Syringe

1.5 ML brodalumab 140 MG/ML Prefilled Syringe [Siliq]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Siliq is used to treat moderate to severe plaque psoriasis in adults.
Siliq is usually given after other treatments have failed.

Siliq is FDA approved for the following indications: plaque psoriasis, psoriasis. 

Report Adverse Event

Prescribing Information

Medication Guide 

Pharmacy List 

Submit MSL Request 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Enroll in Patient Savings Program 

Bausch Patient Assistance Program Eligibility Check and Enrollment 

Other HCP Resources 

About Siliq 

Taking Siliq 

Before & After 

Patient Stories 

FAQs: Plaque Psoriasis 

Doctor Discussion Guide 

Instructions For Use: Plaque Psoriasis 